← Eichor
Condition: Diffuse Midline Glioma Or Diffuse Intrinsic Pontine Glioma Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Diffuse Midline Glioma Or Diffuse Intrinsic Pontine Glioma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Di
Phase 1 · 20 location(s) · Children's Oncology Group · NCT06894979H3K27M-specific Immune Effector Cells Targeting DMG/DIPG
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT07501156Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Gliom
Phase 1 · 1 location(s) · Seattle Children's Hospital · NCT04185038Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Phase 2 · 20 location(s) · Nationwide Children's Hospital · NCT05843253CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Phase 1/Phase 2 · 35 location(s) · Children's Oncology Group · NCT04870944Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
EARLY_Phase 1 · 18 location(s) · Nationwide Children's Hospital · NCT06333899
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.